Alpha Teknova Inc Stock News

Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year Company raises 2026 revenue guidance to $46-48 million Strengthened balance sheet with $46 million public equity offering completed in October 2026 HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents...

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per sha...

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-da...

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three mont...

Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference

Teknova's Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.